Venöz tromboemboli yönetimine ilişkin ulusal kılavuzlar: Türk Kalp Damar Cerrahisi Derneği, Ulusal Vasküler ve Endovasküler Cerrahi Derneği ve Fleboloji Derneği ortak kılavuzu

Türk Kalp Damar Cerrahisi Derneği, Ulusal Vasküler ve Endovasküler Cerrahi Derneği ve Fleboloji Derneği’nin kanıta dayalı kılavuzlarının amacı, venöz tromboemboli (VTE) tedavisine ilişkin hekimlerin en iyi kararı vermelerini desteklemektir. Üç ulusal dernek tarafından Editör seçilmiş olup, kararlaştırılmış panelin toplanması ile görevlendirilmiştir. Tüm finansal destekler, endüstri veya diğer harici tarafların doğrudan iştiraki olmaksızın, bütünüyle sponsor olan dernekler tarafından sağlanmıştır. Panelde hekimler için VTE açısından önemine göre klinik sorular ve sonuçlar önceliklendirilmiştir. Panelde VTE’nin tanısı, ilk tedavisi, ikincil korunması ve tekrarlayan VTE olaylarının tedavisi olmak üzere, 15 başlık altında 42 öneri üzerinde uzlaşılmıştır. Önemli öneriler arasında ultrasonografi kullanımı, komplike olmayan VTE’nin hastanede tedavisine kıyasla evde tedavi tercihi, primer kanser ve kanser ile ilişkili olmayan VTE tedavisinde vitamin K antagonistlerine kıyasla direkt oral antikoagülanların (DOAK) tercihi, belirli yüksek riskli hastalarda DOAK’lar ile uzun süreli veya süresiz antikoagülasyon yer almıştır. Erken dönemde kateter yönlendirmeli trombektomi, yalnızca taze iliofemoral derin ven tromboz tanısı konan genç semptomatik hastalarda önerilmiştir.

National guidelines on the management of venous thromboembolism: Joint guideline of the Turkish Society of Cardiovascular Surgery, National Society of Vascular and Endovascular Surgery, and Phlebology Society

These evidence-based guidelines from the Turkish Society of Cardiovascular Surgery, National Society of Vascular and Endovascular Surgery, and Phlebology Society intend to support clinicians in best decisions regarding the treatment of venous thromboembolism (VTE). The Editor was selected by the three national societies and was tasked with the recruitment of the recognized panel. All financial support was solely derived from the sponsoring societies without the direct involvement of industry or other external stakeholders. The panel prioritized clinical questions and outcomes according to their importance for clinicians in terms of VTE. The panel agreed on 42 recommendations under 15 headings for the diagnosis, initial management, secondary prevention of VTE, and treatment of recurrent VTE events. Important recommendations included the use of ultrasonography, preference for home treatment over hospital treatment for uncomplicated VTE, preference for direct oral anticoagulants (DOACs) over vitamin K antagonists for primary treatment of cancer and non-cancer-related VTE, extended or indefinite anticoagulation with DOACs in selected high-risk patients. Early catheter-directed thrombectomy was recommended in only young symptomatic patients with a diagnosis of fresh iliofemoral deep vein thrombosis.

PDF

___

1. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis 2016;41:3-14.
2. Kakkos SK, Gohel M, Baekgaard N, Bauersachs R, Bellmunt- Montoya S, Black SA, et al. Editor's choice - European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur J Vasc Endovasc Surg 2021;61:9-82.
3. Polat A, Akay HT, Köksal C, Bozkurt AK, editörler. Damar. İstanbul: Bayçınar Tıbbi Yayıncılık; 2019.
4. Wittens C, Davies AH, Bækgaard N, Broholm R, Cavezzi A, Chastanet S, et al. Editor's choice - management of chronic venous disease: Clinical practice guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 2015;49:678-737.
5. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016;149:315-52.
6. Moll S. Thrombophilia: Clinical-practical aspects. J Thromb Thrombolysis 2015;39:367-78.
7. Prandoni P, Lensing AW, Prins MH, Pesavento R, Piccioli A, Sartori MT, et al. The impact of residual thrombosis on the long-term outcome of patients with deep venous thrombosis treated with conventional anticoagulation. Semin Thromb Hemost 2015;41:133-40.
8. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(2 Suppl):e419S-e496S.
9. Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, Cuker A, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: Treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020;4:4693-738.
10. Othieno R, Okpo E, Forster R. Home versus in-patient treatment for deep vein thrombosis. Cochrane Database Syst Rev 2018;1:CD003076.
11. Becattini C, Agnelli G. Treatment of venous thromboembolism with new anticoagulant agents. J Am Coll Cardiol 2016;67:1941-55.
12. Ertaş F, Kaya H, Kaya Z, Bulur S, Köse N, Gül M, et al. Epidemiology of atrial fibrillation in Turkey: Preliminary results of the multicenter AFTER study. Turk Kardiyol Dern Ars 2013;41:99-104.
13. Sargin M, Tasdemir MM, Kuplay H, Erdogan SB, Tandogar N, Akansel S, et al. Retrospective cohort study for evaluating the INR monitoring patterns in patients with deep vein thrombosis in daily practice: Analysis of 2010-2013 database of a tertiary care center. Phlebology 2019;34:317-23.
14. Sargin M, Erdogan SB, Bastopcu M, Arslanhan G, Tasdemir MM, Orhan G. Cost of healthcare associated with deep vein thrombosis in patients treated with Warfarin in Turkey: 2010- 2013 database analysis of a tertiary care center. Value Health Reg Issues 2019;19:81-6.
15. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011;365:2002-12.
16. Kakkos SK, Kirkilesis GI, Tsolakis IA. Editor's choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: A systematic review and meta-analysis of phase III trials. Eur J Vasc Endovasc Surg 2014;48:565-75.
17. Delluc A, Ianotto JC, Tromeur C, De Moreuil C, Couturaud F, Lacut K, et al. Real-world incidence of cancer following a first unprovoked venous thrombosis: Results from the EPIGETBO study. Thromb Res 2018;164:79-84.
18. Klein A, Shepshelovich D, Spectre G, Goldvaser H, Raanani P, Gafter-Gvili A. Screening for occult cancer in idiopathic venous thromboembolism - systemic review and metaanalysis. Eur J Intern Med 2017;42:74-80.
19. Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: Prevention and treatment in patients with cancer. Blood Adv 2021;5:927-74.
20. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-53.
21. Khorana AA, McCrae KR, Milentijevic D, Fortier J, Nelson WW, Laliberté F, et al. Current practice patterns and patient persistence with anticoagulant treatments for cancerassociated thrombosis. Res Pract Thromb Haemost 2017;1:14-22.
22. Lee AYY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, et al. Tinzaparin vs Warfarin for treatment of acute venous thromboembolism in patients with active cancer: A randomized clinical trial. JAMA 2015;314:677-86.
23. Kirkilesis GI, Kakkos SK, Tsolakis IA. Editor's choice - a systematic review and meta-analysis of the efficacy and safety of anticoagulation in the treatment of venous thromboembolism in patients with cancer. Eur J Vasc Endovasc Surg 2019;57:685-701.
24. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the treatment of cancerassociated venous thromboembolism. N Engl J Med 2018;378:615-24.
25. Marshall A, Levine M, Hill C, Hale D, Thirlwall J, Wilkie V, et al. Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m). J Thromb Haemost 2020;18:905-15.
26. McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost 2020;18:411-21.
27. Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020;382:1599-607.
28. Ageno W, Vedovati MC, Cohen A, Huisman M, Bauersachs R, Gussoni G, et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: Results from the Caravaggio study. Thromb Haemost 2021;121:616-24.
29. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: A systematic review of safety and efficacy. Blood 2005;106:401-7.
30. Douketis J, Tosetto A, Marcucci M, Baglin T, Cosmi B, Cushman M, et al. Risk of recurrence after venous thromboembolism in men and women: Patient level metaanalysis. BMJ 2011;342:d813.
31. Kearon C, Spencer FA, O'Keeffe D, Parpia S, Schulman S, Baglin T, et al. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: A cohort study. Ann Intern Med 2015;162:27-34.
32. Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013;369:1406-15.
33. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013;368:709-18.
34. Romualdi E, Donadini MP, Ageno W. Oral rivaroxaban after symptomatic venous thromboembolism: The continued treatment study (EINSTEIN-extension study). Expert Rev Cardiovasc Ther 2011;9:841-4.
35. Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer- Westendorf J, Bounameaux H, et al. Rivaroxaban or Aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017;376:1211-22.
36. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013;368:699-708.
37. Raskob G, Ageno W, Cohen AT, Brekelmans MP, Grosso MA, Segers A, et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE study. Lancet Haematol 2016;3:e228-36.
38. Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012;366:1959-67.
39. Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012;367:1979-87.
40. Simes J, Becattini C, Agnelli G, Eikelboom JW, Kirby AC, Mister R, et al. Aspirin for the prevention of recurrent venous thromboembolism: The INSPIRE collaboration. Circulation 2014;130:1062-71.
41. Bozkurt AK, editör. Periferik Arter ve Ven Hastalıkları Ulusal Tedavi Kılavuzu 2016. İstanbul: Bayçınar Tıbbi Yayıncılık; 2016.
42. Prins MH, Lensing AWA, Prandoni P, Wells PS, Verhamme P, Beyer-Westendorf J, et al. Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood Adv 2018;2:788-96.
43. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799-808.
44. Schulman S. How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy. Blood 2017;129:3285-93.
45. Monagle P, Cuello CA, Augustine C, Bonduel M, Brandão LR, Capman T, et al. American Society of Hematology 2018 Guidelines for management of venous thromboembolism: Treatment of pediatric venous thromboembolism. Blood Adv 2018;2:3292-316.
46. Halton J, Brandão LR, Luciani M, Bomgaars L, Chalmers E, Mitchell LG, et al. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): A randomised, controlled, open-label, phase 2b/3, noninferiority trial. Lancet Haematol 2021;8:e22-e33.
47. Young G, Lensing AWA, Monagle P, Male C, Thelen K, Willmann S, et al. Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation. J Thromb Haemost 2020;18:1672-85.
48. Mujer MTP, Rai MP, Atti V, Dimaandal IL, Chan AS, Shrotriya S, et al. An update on the reversal of nonvitamin K antagonist oral anticoagulants. Adv Hematol 2020;2020:7636104.
49. Zada I, Wang S, Akerman M, Hanna A. Four-factor prothrombin complex concentrate for the reversal of direct oral anticoagulants. J Intensive Care Med 2021;36:58-62.
50. Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: A report of the American College of Cardiology solution set oversight committee. J Am Coll Cardiol 2020;76:594-622.
51. Kirkilesis G, Kakkos SK, Bicknell C, Salim S, Kakavia K. Treatment of distal deep vein thrombosis. Cochrane Database Syst Rev 2020;4:CD013422.
52. Galanaud JP, Sevestre MA, Pernod G, Genty C, Richelet S, Kahn SR, et al. Long-term outcomes of cancer-related isolated distal deep vein thrombosis: The OPTIMEV study. J Thromb Haemost 2017;15:907-16.
53. Decousus H, Quéré I, Presles E, Becker F, Barrellier MT, Chanut M, et al. Superficial venous thrombosis and venous thromboembolism: A large, prospective epidemiologic study. Ann Intern Med 2010;152:218-24.
54. Di Nisio M, Wichers IM, Middeldorp S. Treatment for superficial thrombophlebitis of the leg. Cochrane Database Syst Rev 2018;2:CD004982.
55. Duffett L, Kearon C, Rodger M, Carrier M. Treatment of superficial vein thrombosis: A systematic review and metaanalysis. Thromb Haemost 2019;119:479-89.
56. Beyer-Westendorf J, Schellong SM, Gerlach H, Rabe E, Weitz JI, Jersemann K, et al. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: The open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol 2017;4:e105-e113.
57. Decousus H, Prandoni P, Mismetti P, Bauersachs RM, Boda Z, Brenner B, et al. Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med 2010;363:1222-32.
58. Nikolakopoulos KM, Kakkos SK, Papageorgopoulou CP, Tsolakis IA. Extended-duration treatment of superficial vein thrombosis of the lower limbs with Tinzaparin. Vasc Specialist Int 2018;34:1-9.
59. Houghton DE, Casanegra AI, Peterson LG, Cochuyt J, Hodge DO, Vlazny D, et al. Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban. Am J Hematol 2020;95:817-23.
60. Schastlivtsev I, Lobastov K, Tsaplin S, Kanzafarova I, Barinov V, Laberko L, et al. Rivaroxaban in the treatment of upper extremity deep vein thrombosis: A single-center experience and review of the literature. Thromb Res 2019;181:24-8.
61. Illig KA, Doyle AJ. A comprehensive review of Paget- Schroetter syndrome. J Vasc Surg 2010;51:1538-47.
62. Enden T, Haig Y, Kløw NE, Slagsvold CE, Sandvik L, Ghanima W, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): A randomised controlled trial. Lancet 2012;379:31-8.
63. Vedantham S, Goldhaber SZ, Julian JA, Kahn SR, Jaff MR, Cohen DJ, et al. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med 2017;377:2240-52.
64. Notten P, Ten Cate-Hoek AJ, Arnoldussen CWKP, Strijkers RHW, de Smet AAEA, Tick LW, et al. Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): A single-blind, multicentre, randomised trial. Lancet Haematol 2020;7:e40-e49.
65. Kahn SR, Julian JA, Kearon C, Gu CS, Cohen DJ, Magnuson EA, et al. Quality of life after pharmacomechanical catheterdirected thrombolysis for proximal deep venous thrombosis. J Vasc Surg Venous Lymphat Disord 2020;8:8-23.e18.
66. Kearon C, Gu CS, Julian JA, Goldhaber SZ, Comerota AJ, Gornik HL, et al. Pharmacomechanical catheterdirected thrombolysis in acute femoral-popliteal deep vein thrombosis: Analysis from a Stratified randomized trial. Thromb Haemost 2019;119:633-44.
67. Grommes J, Strijkers R, Greiner A, Mahnken AH, Wittens CH. Safety and feasibility of ultrasound-accelerated catheterdirected thrombolysis in deep vein thrombosis. Eur J Vasc Endovasc Surg 2011;41:526-32.
68. Mismetti P. Randomized trial assessing the efficacy of the partial interruption of the inferior vena cava by an optional vena caval filter in the prevention of the recurrence of pulmonary embolism. PREPIC 2 trial: Prevention of embolic recurrences by caval interruption (prospective, multicentric, randomised, open trial). Rev Pneumol Clin 2008;64:328-31.
69. Kaufman JA, Barnes GD, Chaer RA, Cuschieri J, Eberhardt RT, Johnson MS, et al. Society of interventional radiology clinical practice guideline for inferior vena cava filters in the treatment of patients with venous thromboembolic disease: Developed in collaboration with the American College of Cardiology, American College of Chest Physicians, American College of Surgeons Committee on Trauma, American Heart Association, Society for Vascular Surgery, and Society for Vascular Medicine. J Vasc Interv Radiol 2020;31:1529-44.
70. Kahn SR, Shapiro S, Wells PS, Rodger MA, Kovacs MJ, Anderson DR, et al. Compression stockings to prevent postthrombotic syndrome: A randomised placebo-controlled trial. Lancet 2014;383:880-8.
71. Ten Cate-Hoek AJ, Amin EE, Bouman AC, Meijer K, Tick LW, Middeldorp S, et al. Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): A multicentre, randomised, single-blind, allocation-concealed, noninferiority trial. Lancet Haematol 2018;5:e25-e33.
72. Amin EE, Bistervels IM, Meijer K, Tick LW, Middeldorp S, Mostard G, et al. Reduced incidence of vein occlusion and postthrombotic syndrome after immediate compression for deep vein thrombosis. Blood 2018;132:2298-304.
73. Malec K, Broniatowska E, Undas A. Direct oral anticoagulants in patients with antiphospholipid syndrome: A cohort study. Lupus 2020;29:37-44.
74. Stevens SM, Woller SC, Bauer KA, Kasthuri R, Cushman M, Streiff M, et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis 2016;41:154-64.